SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Kucknoor Ashwini S.)
 

Sökning: WFRF:(Kucknoor Ashwini S.) > Stampfer Meir J. > Prospective study o...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00005941naa a2200481 4500
001oai:DiVA.org:oru-41456
003SwePub
008150114s2009 | |||||||||||000 ||eng|
009oai:prod.swepub.kib.ki.se:119525741
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-414562 URI
0247 a https://doi.org/10.1093/jnci/djp3062 DOI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:1195257412 URI
040 a (SwePub)orud (SwePub)ki
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Stark, Jennifer R.u Department of Epidemiology, Harvard School of Public Health, Boston, USA; Channing Laboratory, Department of Medicine, Brigham and Women´s Hospital and Harvard Medical School, Boston, USA4 aut
2451 0a Prospective study of Trichomonas vaginalis infection and prostate cancer incidence and mortality :b Physicians' Health Study
264 c 2009-09-09
264 1a Cary, USA :b Oxford University Press,c 2009
338 a print2 rdacarrier
520 a Background: A recent nested case-control study found that the presence of antibodies against Trichomonas vaginalis, a common nonviral sexually transmitted infection, was positively associated with subsequent incidence of prostate cancer. We confirmed these findings in an independent population and related serostatus for antibodies against T vaginalis to prostate cancer incidence and mortality.Methods: We conducted a case-control study nested within the Physicians' Health Study that included 673 case subjects with prostate cancer and 673 individually matched control subjects who had available plasma samples. Plasma from blood samples collected at baseline was assayed for antibodies against T vaginalis with an enzyme-linked immunosorbent assay. We used conditional logistic regression to estimate the odds ratios (ORs) of incident prostate cancer, extraprostatic prostate cancer, and cancer that would ultimately progress to bony metastases or prostate cancer-specific death.Results: Although not statistically significant, the magnitude of the association between T vaginalis-seropositive status and overall prostate cancer risk (OR = 1.23, 95% confidence interval [CI] = 0.94 to 1.61) was similar to that reported previously. Furthermore, a seropositive status was associated with statistically significantly increased risks of extraprostatic prostate cancer (OR = 2.17, 95% CI = 1.08 to 4.37) and of cancer that would ultimately progress to bony metastases or prostate cancer-specific death (OR = 2.69, 95% CI = 1.37 to 5.28).Conclusions: This large prospective case-control study obtained further support for an association between a seropositive status for antibodies against T vaginalis and the risk of prostate cancer, with statistically significant associations identified for the risk of extraprostatic prostate cancer and for clinically relevant, potentially lethal prostate cancer.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
7001 a Judson, Gregoryu Department of Epidemiology, Harvard School of Public Health, Boston, USA4 aut
7001 a Alderete, John F.u School of Molecular Biosciences, Washington State University, Pullman, USA4 aut
7001 a Mundodi, Vasanthakrishnau Molecular Biosciences, Washington State University, Pullman, USA4 aut
7001 a Kucknoor, Ashwini S.u Molecular Biosciences, Washington State University, Pullman, USA4 aut
7001 a Giovannucci, Edward L.u Department of Epidemiology, Harvard School of Public Health, Boston, USA; Department of Nutrition, School of Public Health, Boston, USA; Channing Laboratory, Department of Medicine, Brigham and Women´s Hospital and Harvard Medical School, Boston, USA4 aut
7001 a Platz, Elizabeth A.u Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, USA4 aut
7001 a Sutcliffe, Siobhanu Alvin J. Siteman Cancer Center and Department of Surgery, Washington University School of Medicine, St. Louis, USA4 aut
7001 a Fall, Katja,d 1971-u Karolinska Institutet4 aut0 (Swepub:oru)kafl
7001 a Kurth, Tobiasu Department of Epidemiology, Harvard School of Public Health, Boston, USA; Division of Preventive Medicine, Department of Medicine, Brigham and Women´s Hospital and Harvard Medical School, Boston; Institut National de la Santé et de la Recherche Médicale, Unit 708 Neuroepidemiology and Pierre et Marie Curie University, Paris, France4 aut
7001 a Ma, Jingu Channing Laboratory, Department of Medicine, Brigham and Women´s Hospital and Harvard Medical School, Boston, USA4 aut
7001 a Stampfer, Meir J.u Department of Nutrition, School of Public Health, Boston, USA; Channing Laboratory, Department of Medicine, Brigham and Women´s Hospital and Harvard Medical School, Boston, USA4 aut
7001 a Mucci, Lorelei A.u Channing Laboratory, Department of Medicine, Brigham and Women´s Hospital and Harvard Medical School, Boston, USA4 aut
7102 a Department of Epidemiology, Harvard School of Public Health, Boston, USA; Channing Laboratory, Department of Medicine, Brigham and Women´s Hospital and Harvard Medical School, Boston, USAb Department of Epidemiology, Harvard School of Public Health, Boston, USA4 org
7730 t Journal of the National Cancer Instituted Cary, USA : Oxford University Pressg 101:20, s. 1406-11q 101:20<1406-11x 0027-8874x 1460-2105
8564 u https://academic.oup.com/jnci/article-pdf/101/20/1406/18084834/djp306.pdf
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-41456
8564 8u https://doi.org/10.1093/jnci/djp306
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:119525741

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy